CHRS Q4 2021 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M-33.6% YoY

Gross Profit

$61M83.5% margin

Operating Income

-$40M-53.9% margin

Net Income

-$46M-62.3% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-11.1%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$53M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$679M

Total Liabilities

$582M

Stockholders' Equity

$98M

Cash & Equivalents

$417M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$110M	-33.6%
Gross Profit	$61M	$99M	-38.0%
Operating Income	-$40M	$16M	-340.8%
Net Income	-$46M	$10M	-571.0%

Revenue Segments

Product Revenue

$73M100%